{"category":{"kind":"industry","slug":"regenerative-medicine","name":"Regenerative Medicine","tagline":null,"description":null,"synonyms":[],"target_queries":[],"added_via":"web","added_at":"2026-09-21T14:50:17.463Z","updated_at":"2026-09-21T14:50:17.463Z","example":false,"profile_url":"/industries/regenerative-medicine","is_stub":true,"member_count":3,"member_counts":{"company":3}},"members":[{"listing_type":"company","name":"Virelion Biotech","slug":"virelion-biotech","tagline":"Engineering The Heart","description":"Virelion Biotech is an early-stage biotechnology venture building computational and experimental infrastructure for cardiac regeneration, cardiovascular phenotyping, translational research, and biological decision support. Its modular research stack connects cardiac data and evidence, experimental design, biological measurement, machine learning, benchmarking, evaluation, simulation, provenance, and interoperability.","url":"https://virelionbiotech.netlify.app/","is_stealth":false,"normalized_domain":"virelionbiotech.netlify.app","normalized_url_key":"virelionbiotech.netlify.app","parent_slug":null,"parent":null,"type_data":{},"logo":null,"links":[{"label":"X / Twitter","url":"https://x.com/VirelionBiotech","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/virelion/","platform":"linkedin"},{"label":"Instagram","url":"https://www.instagram.com/virelionbiotech/","platform":"instagram"}],"entry_points":[{"kind":"homepage","url":"https://virelionbiotech.netlify.app/","audience":"any","primary":false,"listed_by":"owner","derived_from":"url","on_listing_domain":true},{"kind":"github","url":"https://github.com/Virelion-Biotech","audience":"any","primary":false,"listed_by":"owner","derived_from":"github","on_listing_domain":false}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://virelionbiotech.netlify.app/","audience":"any","primary":false,"listed_by":"owner","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[{"person_slug":"syed-umer-hannan-3fblh9ry0wa0i","name":"Syed Umer Hannan","role":"CEO","bio":null,"location":null,"image_url":null,"image_asset_id":null,"links":[]}],"media":{"logo_asset_id":"afde59ab-e89b-41a3-a020-ef010a06040e","cover_asset_id":"84b21595-2a73-4f76-a4bb-4f91cb6ab830","screenshot_asset_ids":[]},"categories":["Biotech","Life Sciences","AI","Deep Tech","Healthcare","Biomedical Engineering","Research","Regenerative Medicine"],"stage":"pre-seed","founded_year":2024,"location":"United States","pricing":"Free","twitter":null,"github":"https://github.com/Virelion-Biotech","linkedin":null,"contact_email":"virelion85@gmail.com","added_at":"2026-09-23T15:12:56.531Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"verified","claimed_by_agent_id":null,"claimed_via_claim_id":"cfd71606-484a-4cc6-9e3b-36d9903241bc","claimed_at":"2026-09-23T15:17:45.470Z","updated_at":"2026-09-23T15:17:45.470Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biomedical-engineering","name":"Biomedical Engineering","note":null,"profile_url":"/industries/biomedical-engineering"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"deep-tech","name":"Deep Tech","note":null,"profile_url":"/industries/deep-tech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"life-sciences","name":"Life Sciences","note":null,"profile_url":"/industries/life-sciences"},{"kind":"industry","slug":"regenerative-medicine","name":"Regenerative Medicine","note":null,"profile_url":"/industries/regenerative-medicine"},{"kind":"industry","slug":"research","name":"Research","note":null,"profile_url":"/industries/research"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-23T15:12:56.531Z","updated_at":"2026-09-23T15:12:56.531Z"}},{"listing_type":"company","name":"Celaid Therapeutics","slug":"celaid-therapeutics","tagline":"Expanded hematopoietic stem-cell therapies for blood diseases and genetic disorders","description":"Celaid Therapeutics is a Tokyo-based biotech developing cell therapies built on hematopoietic stem cells (HSCs), the stem cells that produce blood. Its in-vitro expansion technology grows functional, blood-reconstituting HSCs in large quantities without animal-derived components such as albumin and cytokines, aiming to make high-quality cells available at lower cost. Its lead program, CLD-001, is an ex vivo-expanded HSC therapy from umbilical cord blood for severe pediatric non-malignant diseases; the company has reported positive nonclinical data, transferred manufacturing to a U.S. CDMO and completed a pre-IND meeting with the FDA. Established in October 2020 and led by President and CEO Nobuyuki Arakawa, Celaid announced on October 5, 2026 the second close of its Series B, raising JPY 400 million (about USD 2.6 million) from new investors Shionogi and Teikoku Ventures, bringing cumulative funding including AMED grants to about JPY 3.42 billion.","url":"https://celaidtx.com/en/","is_stealth":false,"normalized_domain":"celaidtx.com","normalized_url_key":"celaidtx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://celaidtx.com/wp/wp-content/themes/celaid/img/ogp_en.jpg","links":[{"label":"Series B second close announcement","url":"https://celaidtx.com/en/news/1204/"},{"label":"Press release (PR Newswire)","url":"https://www.prnewswire.com/news-releases/celaid-therapeutics-completes-second-close-of-series-b-financing-round-302893509.html"},{"label":"Shionogi investment announcement","url":"https://www.shionogi.com/global/en/news/2026/10/20261005.html"}],"entry_points":[{"kind":"homepage","url":"https://celaidtx.com/en/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},{"kind":"contact","url":"https://celaidtx.com/en/contact/","audience":"human","primary":false,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://celaidtx.com/en/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},"agent":{"kind":"homepage","url":"https://celaidtx.com/en/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}},"founders":[{"name":"Nobuyuki Arakawa","role":"President and CEO","person_slug":"nobuyuki-arakawa-0qsnwpq1jn9r3","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"a0990521-c2d9-49d3-aae0-aee0845c1455"},"categories":["Biotech","Cell Therapy","Regenerative Medicine"],"stage":"series-b+","founded_year":2020,"location":"Tokyo, Japan","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-10-06T01:22:59.595Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-06T01:22:59.595Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"cell-therapy","name":"Cell Therapy","note":null,"profile_url":"/industries/cell-therapy"},{"kind":"industry","slug":"regenerative-medicine","name":"Regenerative Medicine","note":null,"profile_url":"/industries/regenerative-medicine"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-06T01:22:59.595Z","updated_at":"2026-10-06T01:22:59.595Z"}},{"listing_type":"company","name":"Novadip Biosciences","slug":"novadip-biosciences","tagline":"Tissue regenerative medicine for severe bone defects","description":"Novadip Biosciences is a Belgian biotech developing regenerative therapies to repair severe bone defects. Its lead program NVD003 is an autologous cell-based therapy for congenital pseudarthrosis of the tibia and is in a pivotal Phase 3 study in the United States and Europe.","url":"https://novadip.com/","is_stealth":false,"normalized_domain":"novadip.com","normalized_url_key":"novadip.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://novadip.com/wp-content/uploads/2022/09/cropped-20200406-Novadip-Logo-vertical-270x270.png","links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/novadip-biosciences-s-a-","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://novadip.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://novadip.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"8895ac2f-223e-4b69-82d6-efdf8c8470d4"},"categories":["Biotechnology","Regenerative Medicine","Health"],"stage":null,"founded_year":null,"location":"Louvain-la-Neuve, Belgium","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/novadip-biosciences-s-a-","contact_email":null,"added_at":"2026-09-21T14:50:17.463Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-21T14:50:17.463Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotechnology","name":"Biotechnology","note":null,"profile_url":"/industries/biotechnology"},{"kind":"industry","slug":"health","name":"Health","note":null,"profile_url":"/industries/health"},{"kind":"industry","slug":"regenerative-medicine","name":"Regenerative Medicine","note":null,"profile_url":"/industries/regenerative-medicine"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-21T14:50:17.463Z","updated_at":"2026-09-21T14:50:17.463Z"}}],"total":3,"limit":50,"offset":0}